Rapid Medical’s Tigertriever 17 Ultra Receives CE Mark Approval for Stroke Treatment

September 25, 2026—Rapid Medical announced in a social media post that its Tigertriever 17 Ultra has received CE Mark approval, expanding its portfolio of adjustable clot retrievers for ischemic stroke. The company advised that the device is immediately available in the European market.

In the United States, the Tigertriever 17 Ultra received FDA 510(k) clearance in September 2025 and the initial commercial case with the device was performed in January 2026, noted Rapid Medical.

According to the company, the Tigertriever 17 Ultra device is intended to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for thrombolytic drug therapy or who failed thrombolytic drug therapy are candidates for treatment.

Rapid Medical stated that Tigertriever 17 Ultra is 45% longer than the standard Tigertriever 17 device, extending its clot capture area.

The Tigertriever platform is designed to allow physicians to expand the device for clot engagement and ease the outward pressure before retrieval. With the combination of high force for clot capture and the low force during retrieval, the platform addresses the usual design tradeoff between engaging the clot and limiting traction on the vessel, noted the company.